⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1189859 | 1.00 | — | — | |
| SCHEMBL1641311 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL2886007 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL2886006 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL5269479 | 0.97 | — | — | |
| SCHEMBL4932955 | 0.92 | — | — | |
| Bromide SCHEMBL29090935 | 0.90 | — | — | |
| Bromide SCHEMBL29090936 | 0.90 | — | — | |
| SCHEMBL26063476 | 0.90 | CYP2D6 (0.52) | — | |
| SCHEMBL5163698 | 0.80 | CHRNA3 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4387963-B1 | PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 | REDX PHARMA LTD (GB) | 2025-12-24 | — | — | EP | disclosed |
| WO-2025072539-A1 | AMINO ACID COMPOUNDS WITH NITROGEN LINKERS AND USES THEREOF | PLIANT THERAPEUTICS, INC. (US) | 2025-04-03 | — | — | WO | disclosed |
| US-20240336592-A1 | PHENYL- AND PYRIDOPYRAZOLE DERIVATIVES AS INHIBITORS OF DDR1 | REDX PHARMA PLC (GB) | 2024-10-10 | — | — | US | disclosed |
| CN-117858707-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-4319756-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| WO-2023079291-A1 | DDR1 AND DDR2 INHIBITORS FOR THE TREATEMENT OF CANCER AND FIBROTIC DISEASES | REDX PHARMA PLC (GB) | 2023-05-11 | — | — | WO | disclosed |
| US-20230086064-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2022148422-A1 | BRIDGED COMPOUNDS AS KRAS G12D INHIBITOR AND DEGRADER AND THE USE THEREOF | BEIGENE, LTD. (KY) | 2022-07-14 | — | — | WO | disclosed |
| US-11040954-B1 | CXCR3 receptor agonists | RECEPTOS LLC (US) | 2021-06-22 | — | — | US | disclosed |
| EP-2909198-B1 | BICYCLIC HETEROCYCLE COMPOUNDS AND THEIR USES IN THERAPY | ASTEX THERAPEUTICS LTD (GB) | 2020-10-14 | — | — | EP | disclosed |
| US-7153889-B2 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES (US) | 2006-12-26 | — | — | US | disclosed |
| US-20060194798-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2006-08-31 | — | — | US | disclosed |
| US-6969730-B2 | Amines as histamine-3 receptor ligands and their therapeutic applications | ABBOTT LABORATORIES (US) | 2005-11-29 | — | — | US | disclosed |
| WO-2005097740-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2005-10-20 | — | — | WO | disclosed |
| EP-1569637-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | Abbott Laboratories (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050192277-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2005-09-01 | — | — | US | disclosed |
| US-20040152704-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBVIE INC. | 2004-08-05 | — | — | US | disclosed |
| WO-2004043458-A1 | BICYCLIC-SUBSTITUTED AMINES AS HISTAMINE-3 RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2004-05-27 | — | — | WO | disclosed |
| US-20040092521-A1 | Bicyclic-substituted amines as histamine-3 receptor ligands | ABBOTT LABORATORIES | 2004-05-13 | — | — | US | disclosed |
| US-20020169188-A1 | Novel amines as histamine-3 receptor ligands and their therapeutic applications | ABBVIE INC. | 2002-11-14 | — | — | US | disclosed |